Literature DB >> 31871009

LGI-1 antibody encephalitis in a seven-year-old girl.

Ali Mir1, Ziyad Thani1, Shahid Bashir2, Hana Ayed1, Raidah Albaradie1.   

Abstract

LGI-1 antibody encephalitis is a rare autoimmune limbic encephalitis which has been reported predominantly in adults. Seizures in LGI-1 antibody encephalitis exhibit significant semiological variability. Faciobrachial dystonic seizures are characteristically seen in this condition and have so far been described only in adults. Other seizure types have also been reported. We describe the case of a seven-year-old girl with LGI-1 limbic encephalitis who presented with acute new-onset seizures, and rapidly deteriorated over the course of a few weeks with very frequent seizures and encephalopathy, becoming non-verbal and non-ambulatory. The electroclinical presentation of this child with LGI-1 encephalitis makes this case unique and further highlights the importance of a high index of suspicion for diagnosis in young children. Early diagnosis can lead to prompt and appropriate treatment with immunotherapy, and potential harmful treatments such as pharmacological coma can be avoided. To the best of our knowledge, this is the youngest case ever reporter. [Published with video sequences].

Entities:  

Keywords:  FBDS; LGI-1; VGKC; faciobrachial dystonic seizure; leucine-rich glioma-inactivated 1 encephalitis

Mesh:

Substances:

Year:  2019        PMID: 31871009     DOI: 10.1684/epd.2019.1117

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  2 in total

1.  Faciobrachial Dystonic Seizures as a Sign of Relapse in a Child with LGI-1 Encephalitis.

Authors:  Wajd Alotaibi; Shahid Bashir; Ali Mir
Journal:  Child Neurol Open       Date:  2022-06-03

2.  Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review.

Authors:  Yuou Teng; Ting Li; Zhizhong Yang; Mingwan Su; Jingnian Ni; Mingqing Wei; Jing Shi; Jinzhou Tian
Journal:  Front Neurol       Date:  2022-01-12       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.